Nektar Therapeutics (NKTR) — Who Owns This Stock? 13F Breakdown (Q2 2026)

NKTR ranks #2525 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

NKTR is a top-conviction position for 22nw, LP — at 18.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in NKTR belongs to FMR LLC, but the position matters far more to 22nw, LP, who has 18.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its NKTR position for two straight quarters, increasing it by $349.5M to reach $353.8M today.

NKTR is up 0.5% today, and institutions have been net buyers of $907.3M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

NKTR reported a net loss of $157.1M over the trailing twelve months.

• Not yet profitable — net loss of $157.1M over the trailing twelve months
• Revenue declined 27.2% year over year
• Net income declined year over year, from -$122.3M to -$157.1M
• Operating cash flow was negative, using $208.5M in cash
• Current ratio of 4.97x — enough short-term assets to cover short-term liabilities
• Liabilities run 2.12x equity — a highly leveraged balance sheet worth noting